Shanghai, China – Broda Technologies Co., Ltd. today announced it has entered into a licensing agreement with Redwood Pharma AB of Sweden for its proprietary IntelliGel drug delivery system for use in Redwood Pharma’s lead chronic Dry Eye therapeutic currently under development and other ophthalmic therapies.
IntelliGel is a smart supramolecular hydrogel drug delivery system designed for the delivery of a reverse thermo-responsive hydrogel that is capable of transforming from a liquid to a shear-sensitive hydrogel at desirable physiologically useful temperatures. It is also capable of dissolving water insoluble or sparely soluble active pharmaceutical ingredients in water with sustained release. The delivery system has significant potential in a wide variety of applications with enhanced efficacy, patient compliance, and safety comparing with existing pharmaceutical delivery systems.
“By entering into the licensing agreement, Redwood Pharma will be able to use Broda’s novel IntelliGel® smart delivery technology for its lead chronic Dry Eye therapeutic currently under development and other ophthalmic therapies.” stated Broda Technologies President Dr. Shao Lu.
About Broda Technologies
Broda Technologies Co., Ltd. is a small start-up company focused on smart supramolecular drug delivery systems. The Company’s proprietary IntelliGel® supramolecular drug delivery technology is capable of dissolving water insoluble or sparely soluble drugs in a clear and transparent smart hydrogel with enhanced efficacy, safety and patient’s compliance. For more information, please visit www.brodatech.com.
Contact
Broda Technologies, Co., Ltd.
Shao Lu, Ph.D.
Tel: +86 21 2022 5388
E-mail: sxlu@brodatech.com
www.brodatech.com
Find out how our breakthrough smart supramolecular drug delivery plateform technology can help you maximizing potential of your development drug and related consumer care products.
Email: